Abstract:Objectives To detect the early subclinical myocardial injury during and shortly after epirubicin exposure in asymptomatic patients with large B-cell non-Hodgkin lymphoma by two-dimensional speckle tracking imaging and high sensitive cardiac troponin T (hs-cTnT) and to investigate whether alterations of myocardial strains and high sensitive cardiac troponin T could predict future cardiac dysfunction in patients after epirubicin exposure. Methods Seventy-five patients aged 53.9 ± 13.8 years with newly-diagnosed large B-cell non-Hodgkin lymphoma treated with anthracycline were studied. Blood collection and echocardiography were performed at baseline, 1 day after the third cycle, and 1 day after chemotherapy completion. After 4–6 months of chemotherapy, echocardiography was followed up. Levels of cTnT were detected with a highly sensitive assay. Longitudinal (LS), circumferential (CS) and radial strain (RS) were calculated using two-dimensional speckle tracking echocardiography. Left ventricular ejection fraction (LVEF) was analysed by real-time 3D echocardiography. Cardiotoxicity was defined according to the guidelines (Cardiac Review and Evaluation Committee of Trastuzumab-associated cardiotoxicity, CREC) as a reduction of the left ventricular ejection fraction (LVEF) of ≥5% to <55% with symptoms of heart failure or an asymptomatic reduction of the LVEF of ≥10% to <55%. Results LVEF remained stable and within normal limits in the whole course of chemotherapy. However it was decreased from 65.0 ± 3.8% at baseline to 60.8 ± 4.9% during follow-up (p = 0.000). Fourteen patients (18.67%) developed cardiotoxicity 4–6 months after treatment. Global LS (-18.5 ± 1.7% vs -16.5 ± 1.9%), CS (-20.9 ± 2.9% vs -19.3 ± 3.5%), RS (39.2 ± 6.4% vs 35.3 ± 5.2%) were markedly reduced and cTnT was elevated from 0.0010 ± 0.0020 ng/ml to 0.0063 ± 0.0089 ng/ml (p all<0.01) at the completion of the third cycle of chemotherapy compared with baseline values. The correlation between the increment of cTnT levels and percentage of global LS deduction was good (rho = 0.60, p < 0.01), and percentage of CS and RS decrease was modest (rho = 0.31, -0.29, respectively, p all <0.01). A >15.9% decrease in longitudinal strain ( sensitivity: 86%, specificity: 75%, AUC = 0.815, P = 0.001) and a >0.004ng/ml elevation in cTnT levels (sensitivity: 79%, specificity: 64%, AUC = 0.757, P = 0.005) from baseline to the third cycle of chemotherapy predicted later cardiotoxicity. The decrease of longitudinal strain between baseline and the third cycle of chemotherapy remained the only independent predictor of cardiotoxicity (p = 0.000). Conclusions Two-dimensional speckle tracking imaging combined with high sensitive cTnT may provide a reliable and accurate non-invasive method to detect subtle myocardial injury and to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy. The decrease of longitudinal strain is the only independent predictor of cardiotoxicity.

Early Anthracycline-Induced Cardiotoxicity Monitored by Echocardiographic Doppler Parameters Combined with Serum Hs-Ctnt.

P2429Echocardiographic Tei Index Combined with Serum High-Sensitivity Troponin T Assay for Early Diagnosis of Anthracycline-Induced Cardiotoxicity

Estimation of the value of echocardiographic Tei index combined with serum high-sensitivity cardiac troponin T assay in early diagnosis of anthracycline-induced cardiotoxicity

Use of echocardiography to monitor myocardial damage during anthracycline chemotherapy

GW24-e1764 Speckle Tracking Imaging Combined with High Sensitive Cardiac Troponin T in Early Detection and Prediction of Cardiotoxicity During Anthracycline-based Chemotherapy

Early Detection of the Cardiotoxicity Induced by Chemotherapy Drug Through Two-Dimensional Speckle Tracking Echocardiography Combined with High-Sensitive Cardiac Troponin T

[Evaluation of Early Monitoring of Cardiotoxicity Induced by Anthracyclines].

Two‐dimensional Speckle Tracking Echocardiography Combined with High‐sensitive Cardiac Troponin T in Early Detection and Prediction of Cardiotoxicity During Epirubicine‐based Chemotherapy

Echocardiography Monitoring during Anthracycline Administration in Hodgkin and Non-Hodgkin’s Lymphoma: The Tei Index Evaluation

Early detection of chemotherapy-induced cardiotoxicity in breast cancer patients: a comprehensive analysis using speckle tracking echocardiography

Early detection of cardiotoxicity by 3D speckle tracking imaging of area strain in breast cancer patients receiving chemotherapy

Early Detection of Anthracycline-Induced Cardiotoxicity Using Two-Dimensional Speckle Tracking Echocardiography.

Early Subclinical Dysfunction of Right Cardiac System Induced by Anthracycline Manifested As Morphological Changes

Subclinical Anthracycline-Induced Cardiotoxicity in the Long - Term Follow-Up of Lymphoma Survivors: A Multi-Layer Speckle Tracking Analysis.

Assessment of predictors of anthracycline-induced heart failure

Assessment of left heart dysfunction to predict doxorubicin cardiotoxicity in children with lymphoma

High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury

Two-dimensional speckle tracking echocardiography help identify breast cancer therapeutics-related cardiac dysfunction

Correlation of Mean Heart Dose and Cardiac Biomarkers with Electrocardiographic Changes in Patients Receiving Thoracic Radiation Therapy

Anthracycline Induced Inconsistent Left Ventricular Segmental Systolic Function Variation in Patients with Lymphoma Detected by Three-Dimensional Speckle Tracking Imaging